Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

NCT03439670 is registered in ClinicalTrials.gov with ReveraGen BioPharma, Inc. as lead sponsor.

NCT NCT03439670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
ReveraGen BioPharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2018
Completion date
August 19, 2021
Enrollment
121 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy